Development of new strategies of human antitumor dendritic cell vaccines

Project Information

MYRTO-GEORDIA TRAKAT

Grant agreement ID: QLK2-CT-1999-51390

Project closed

Start date 1 August 2000

End date 31 July 2002

Funded under

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Total cost € 159 400,00

EU contribution € 159 400,00

Coordinated by

UNIVERSITE LIBRE DE BRUXELLES
Belgium

Objective

The project aims to investigate in healthy donors and in melanoma patients, strategies that could improve the generation of MAGE-specific antitumor cytotoxic immune responses by vaccination with autologous dendritic cells.

Fields of science

• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Call for proposal

Data not available

Funding Scheme

RGI - Research grants (individual fellowships)

Coordinator

UNIVERSITE LIBRE DE BRUXELLES

• EU contribution: No data
• Address: Route de Lennik 808 ; 1070 BRUXELLES ; Belgium
• Total cost: No data